1
MRM’s platform could optimise the link between the gut microbiome and cancer outcomes
MRM Health, a clinical-stage biopharmaceutical company developing microbiome-based therapeutics for inflammatory diseases and immuno-oncology, has announced its collaboration with Professor Emile Voest, senior group leader at the Netherlands Cancer Institute (NKI) and senior investigator at Oncode Institute.
MRM hopes to accelerate the development of novel live biotherapeutic products (LBPs) to improve the efficacy of immune checkpoint inhibitors (ICIs) in cancer treatment, assisted by Voest’s…